Evidence map›Paper›PMID 33735175›Full record

ArticlePloS one2021

Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads.

Ivan Francisco Loncarevic, Susanne Toepfer, Stephan Hubold, Susanne Klingner, Lea Kanitz, Thomas Ellinger, Katrin Steinmetzer, Thomas Ernst, Andreas Hochhaus, Eugen Ermantraut

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ivan Francisco LoncarevicBLINK AG, Jena, Germany.ORCID 0000-0002-2763-5765
Susanne ToepferBLINK AG, Jena, Germany.
Stephan HuboldBLINK AG, Jena, Germany.
Susanne KlingnerBLINK AG, Jena, Germany.
Lea KanitzBLINK AG, Jena, Germany.
Thomas EllingerBLINK AG, Jena, Germany.
Katrin SteinmetzerBLINK AG, Jena, Germany.
Thomas ErnstUniversitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Jena, Germany.
Andreas HochhausUniversitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Jena, Germany.
Eugen ErmantrautBLINK AG, Jena, Germany.
Jena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precise quantification of molecular targets in a biological sample across a wide dynamic range is a key requirement in many diagnostic procedures, such as monitoring response to therapy or detection of measurable residual disease. State of the art digital PCR assays provide for a dynamic range of four orders of magnitude. However digital assays are complex and require sophisticated microfluidic tools. Here we present an assay format that enables ultra-precise quantification of RNA targets in a single measurement across a dynamic range of more than six orders of magnitude. The approach is based on hydrogel beads that provide for microfluidic free compartmentalization of the sample as they are used as nanoreactors for reverse transcription, PCR amplification and combined real time and digital detection of gene transcripts. We have applied these nanoreactor beads for establishing an assay for the detection and quantification of BCR-ABL1 fusion transcripts. The assay has been characterized for its precision and linear dynamic range. A comparison of the new method against conventional real time RT-PCR analysis (reference method) with clinical samples from patients with chronic myeloid leukemia (CML) revealed excellent concordance with Pearsons correlation coefficient of 0.983 and slope of 1.08.

Indexed as

AlgorithmsDNA PrimersFusion Proteins, bcr-ablHumansHydrogelsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNanotechnologyReal-Time Polymerase Chain ReactionRNA, MessengerBCR-ABL1 fusion protein, humanDNA PrimersFusion Proteins, bcr-ablHydrogelsRNA, Messenger

Identifiers

PMID33735175
PMCPMC7971518
OpenAlexW3136399136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.